Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Greenwich LifeSciences, Inc.

Get SEC filing alerts via email and in your feed for Greenwich LifeSciences, Inc.

GLSI

Greenwich LifeSciences, Inc.

About Greenwich LifeSciences, Inc.

Greenwich Lifescienses, Inc. is a biopharmaceutical company developing immunotherapies targeting HER2/neu-expressing cancers, primarily breast cancer. Its lead candidate, GLSI-100 (GP2 + GM-CSF), aims to prevent cancer recurrence through clinical-stage trials, including Phase III. The company focuses on cancer immunotherapy, leveraging immune system activation, with plans for global commercialization and strategic partnerships in oncology markets.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from Greenwich LifeSciences, Inc.

1
1
Greenwich LifeSciences, Inc. Greenwich LifeSciences Reports $5.7 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 2 months ago | 0 comments

2
1
Greenwich LifeSciences, Inc. Greenwich LifeSciences Reports $19.4 Million Net Loss and Expands Clinical Trials

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
Greenwich LifeSciences, Inc. Greenwich LifeSciences Reports Q3 2025 Financial Results with Increased Net Losses

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Greenwich LifeSciences, Inc. Greenwich LifeSciences Reports Increased Net Losses and Operating Expenses in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Greenwich LifeSciences, Inc. Greenwich LifeSciences Reports $3.26 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Greenwich LifeSciences, Inc. Greenwich LifeSciences Reports $15.8 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Greenwich LifeSciences, Inc. Greenwich LifeSciences Reports Decline in Assets, Equity, and Cash Reserves Amid Ongoing Challenges and Strategic Developments

Via official filing (AI summary) | over 1 year ago | 0 comments